Clinical implications of distinct metastasizing preferences of different melanoma subtypes

European Journal of Dermatology

Volumn 24, Issue 2, 2014, Pages 236-241

  Schoenewolf, Nicola L ^a   Belloni, Benedetta ^a   Simcock, Mathew ^b   Tonolla, Sabina ^a   Vogt, Pascale ^a   Scherrer, Ellen ^a   Holzmann, David ^c   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Melanoma metastasis; Melanoma subtypes; Predictive metastatic patterns; Prognostic factors

Indexed keywords

B RAF KINASE;

ACROLENTIGINOUS MELANOMA; ADULT; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; DISTANT METASTASIS; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALIGNANT LENTIGO; MEDICAL PARAMETERS; MELANOMA; MIDDLE AGED; MUCOSAL MELANOMA; MUTATION; PLEURA METASTASIS; SKIN METASTASIS; SUPERFICIALLY SPREADING MELANOMA; SURVIVAL TIME; TIME TO FIRST DISTANT METASTASIS; CANCER STAGING; CLASSIFICATION; COMPARATIVE STUDY; RETROSPECTIVE STUDY; SECONDARY;

ADULT; HUMANS; MELANOMA; NEOPLASM STAGING; RETROSPECTIVE STUDIES;

EID: 84901263922     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2014.2292     Document Type: Article

References (21)

1. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998; 58: 2170-5.
2. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-6.
3. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47.
4. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
5. Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147: 62-70.
6. Reintgen DS, Cox C, Slingluff CL Jr., Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 1992; 28: 45-9.
7. Bulliard J, Panizzon R, Levi F. Epidemiologie und Prävention des Hautmelanoms in der Schweiz. Schweiz Med Forum 2009; 9: 314-8.
8. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31: 578-83.
9. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, Ringborg U. Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol 1999; 38: 549-57.
10. de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 1983; 43: 3427-33.
11. Tejera-Vaquerizo A, Barrera-Vigo MV, Fernandez-Canedo I, et al. [Longitudinal study of different metastatic patterns in the progression of cutaneous melanoma]. Actas Dermosifiliogr 2007; 98: 531-8.
12. Zakrzewski J, Geraghty LN, Rose AE, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 2011; 117: 1711-20.
13. Jakob JA, Bassett JRL, Ng CS, et al. Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. ASCO Abstract ID (Temp Abst ID): 8500(76931) 2011.
14. Thomas AJ, Erickson CA. The making of a melanocyte: the specification of melanoblasts from the neural crest. Pigment Cell Melanoma Res 2008; 21: 598-610.
15. Mohammad KS, Javelaud D, Fournier PG, et al. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res 2011; 71: 175-84.
16. Chapman PB, Hauschild A, Robert C, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 2011; 364: 2507-16.
17. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
18. Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma. J Clin Oncol 2011; 29: 1239-4.
19. Tan A, Moodie K, Kerr L, et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 2010; 102: 1219-23.
20. Schoenewolf NL, Urosevic-Maiwald M, Dummer R. Tumor heterogeneity of mucosal melanomas during treatment with imatinib. Br J Dermatol 2011; 165: 419-424.
21. Koh HK, Michalik E, Sober AJ, et al. Lentigo maligna melanoma has no better prognosis than other types of melanoma. J Clin Oncol 1984; 2: 994-1001.